Over 20 years of successful track record in biotech start-up, drug R&D, and business development. Responsible Person for the two projects supported by China’s 12th and 13th “National 5-Year important Innovations” funding programs; Dual-Innovation Talent of Jiangsu Province
Founding member of Hutchison Medipharma (Shanghai). Served as Senior Director of Medicinal Chemistry and Executive Director of IP, and contributed to the clinical development of two drugs in the US. Later served as Executive Director of the Business Development department and successfully established strategic partnership with Procter & Gamble, MSD Germany, and Eli Lilly and Company. In 2006, served as core member of the IPO team in successfully raising 40 million pounds in the UK stock market
Senior Scientist at Johnson & Johnson and Pfizer, with one responsible drug candidate completed Phase II clinical trial in the US
Ph.D. in bio-organic chemistry from Rutgers, the State University of New Jersey. BS in chemistry from Fudan University
John Zhuang, Ph.D.
Over 20 years of drug development and management experience at big pharmas. Expertise in regulatory affairs, nonclinical safety assessment, and GMP compliance. Substantial people and project management experience
Former Senior Director of Regulatory Affairs at Johnson & Johnson. Led teams in approval or acquisition of multiple drugs and medical devices. Served as Head of Regulatory Affairs and on Management Board of a subsidiary
Former Project Leader in Nonclinical Safety Assessment at Eli Lilly and Company. Supported multiple INDs of oncology drugs. Former Senior Scientist at Procter and Gamble Company
Invited speaker by China FDA at multiple symposiums. Topics included nonclinical safety assessment of new drugs, US 505(2) and OTC regulations, drug-device combination product regulations
PhD in toxicology from Massachusetts Institute of Technology (MIT). MS in physical chemistry and BS in chemistry from Sun Yat-sen University
Susan Wang, Ph.D.
Senior Vice President of Global Business Development
Nearly 25 years of successful track record in new drug R&D, commercialization, corporate development, and strategic planning
VP of Commercial Development at Boston Scientific, responsible for commercialization, business and strategic development in the Asia Pacific region including Greater China
Scientist at ICOS Corporation and contributed to the development of Cialis® for treatment of erectile disfunction. After facilitating the formation of Lilly/ICOS JV, led the clinical pharmacology function to the approval of Cialis® by FDA
Co-founder of Endocyte (later acquired by Novartis)
Ph.D. in Biochemistry from Purdue University, USA. BS in chemistry from Fudan University
Tie-Lin Wang, Ph.D.
Senior Vice President, Head of Discovery Chemistry and Pre-Clinical Development
Nearly 20 years of successful track record in drug discovery with broad expertise in R&D management and strong leadership skills.
Served as Chief Scientific Officer at Luoxin Pharmaceuticals (Shanghai),multiple drug candidates have been advanced to clinical trials under his leadership.
Served as Vice President of drug discovery at ChemPartner and Associate Director at Exelixis in charge of multiple collaborative projects with multinational pharmaceutical companies, with one compound is currently in a Phase II clinical trial.
Served as Associate Director at Exelixis and led his team to drive four compounds into clinical development stages. Among them, Minnebro has been approved and launched in Japan for the treatment of essential hypertension.
Ph.D. degree in organic chemistry from Shanghai Institute of Organic Chemistry, Sinica Academia; postdoctoral training in the U.S. included his research in the lab of Sir Derek Barton, a Nobel laureate, at Texas A&M University.
Co-inventor of more than 70 granted patents.
Alice Chen, Ph.D.
Vice President, Discovery Biology and Head of Translational Research
Over 20 years of experience in the US pharmaceutical/biotech industry with a successful track record in drug discovery and translational research.
Served as a Research Fellow at 23andMe Inc，built up a biology team and led 23andMe’s internal and joint drug discovery effort with GSK in the oncology area ； under her leadership, a portfolio of immuno-oncology drug candidates has successfully advanced in 5 years, including 23andMe’s first and second compounds entering clinical trials；led a biology team at NGM Bio-pharmaceuticals in California and discovered two compounds that entered into pre-clinical development； during her tenure at the Genomics Institute of the Novartis Research Foundation (GNF) in California, she led biology platforms and discovery projects, and made a significant contribution to the discovery of Siponimod, an approved drug for relapsing-remitting and secondary progressive multiple sclerosis.
Ph.D. in Neuroscience from Stanford University, BS in Biology from California Institute of Technology.
Published more than 20 scientific research papers with first-authored publications in prestigious journals such as Nature and Cell.
Yijun Deng, Ph.D.
Vice President of Drug Discovery
Over 20 years of experience in the discovery and development of bioactive molecules with pharmaceutical companies in the USA, including Johnson and Johnson, Viropharma Inc, Tetralogic Pharmaceuticals, and Venatorx Pharmaceuticals
Key member of the team discovered birinapant, a first-in-class IAP antagonist for cancer treatment at Tetralogic Pharmaceuticals
Extensive experience in Drug Substance and Drug Product Process Development and Manufacturing under GMP. Played a key role in CMC support to the clinical development of birinapant (TL32711), Remetinostat (SHP-141), and a new b-lactamase inhibitor
Co-author or co-inventor of more than 30 patents and publications
Ph.D. in chemistry from Case Western Reserve University, Cleveland, Ohio; MS and BS in chemistry from Sun Yat-sen University
Ethan Guo, Ph.D.
Senior Vice President of CMC
Over 20 years of new drug R&D and management experience. Worked at Merial, Aventis, Sanofi and other pharmaceutical companies；Senior Director of Pharmaceutical Development Services at WuXi AppTec/STA
Strong experience in new drug developability assessment, analytical and stability studies, pre-formulation, preclinical and clinical formulation development, especially poorly soluble compounds, CMC, CTD preparation, and outsourcing management
Author of four book chapters and expert reviewer for several international pharmaceutical journals
Ph.D. in Chemistry from Iowa State University, Postdoc Fellow at Pharmacy School, University of Wisconsin-Madison
VP of Sales and Marketing
Over a decade of experience in the pharmaceutical industry such as Baxter,Pfizer, with expertise in commercial launch of new product and market development of mature product.
Served as National Sales and Marketing Director at Pierre Fabre heading up the Oncology Business Unit, SFE and training in China. Successfully driven the rapid growth of oncology business and leading the preparation for the launch of new in China for many years.
Served as Marketing Director,Regional Manager and Sales Director at Roche for 8 years, participated in the strategy development and execution of Herceptin and Xeloda, and successfully launch the gastric cancer as the new indication of Herceptin in China, experienced in building, motivating and managing high performance marketing teams.
Major in Clinical Medicine from Shanghai Jiao Tong University with a Bachelor's Degree; more than 8 years experience as a clinician.